|
 |
Nazwa handlowa |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Acetaflur |
Meksyk |
|
Asoleudox |
Meksyk |
|
Beneflur |
Hiszpania, Meksyk |
|
Fludabin |
Peru |
|
Fludacel |
Indie, Peru |
|
Fludakebir |
Peru |
|
Fludalym |
Turcja |
|
Fludara |
Arabia Saudyjska, Austria, Belgia, Chile, Dania, Egipt, Finlandia, Francja , Holandia, Indie, Iran, Irlandia, KolumbiaKolumbia, Luksemburg, Malezja, Niemcy, nowa Zelandia, Polska, Portugalia, Rumunia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Węgry, Wenezuela, Wielka Brytania, Włochy |
|
Fludarabin |
Islandia, Norwegia, Szwajcaria, Szwecja, Włochy |
|
Fludarabina |
Argentyna, Hiszpania, KolumbiaKolumbia, Peru, Rumunia |
|
Fludarabine |
Belgia, Iran, Kanada, Norwegia, nowa Zelandia, Stany Zjednoczone Ameryki, Szwajcaria |
|
Fludarin |
Indie |
|
Fludarosa |
Argentyna |
|
Forclina |
Peru |
|
Ludabina |
Chile, KolumbiaKolumbia |
|
Mepredin |
Peru |
|
Naprobin |
Indie |
|
Neoflubin |
Iran |
|
|
 |
 |
Bibliografia : Fludarabine phosphate |
|
|
typ |
publikacja |
| 3 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Czasopismo |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Czasopismo |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 492 |
Czasopismo |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Czasopismo |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
Czasopismo |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 3306 |
Czasopismo |
Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2. |
| 3595 |
Laboratorium |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3604 |
Laboratorium |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3637 |
Laboratorium |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3644 |
Laboratorium |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3670 |
Czasopismo |
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30. |
| 3838 |
Laboratorium |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4398 |
Czasopismo |
Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020 |
| 4964 |
Laboratorium |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit.
B BRAUN MELSUNGEN AG 2019 |
|
|
